

Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Growth 2024-2030

<https://marketpublishers.com/r/GC0517890A2DEN.html>

Date: June 2024

Pages: 98

Price: US\$ 3,660.00 (Single User License)

ID: GC0517890A2DEN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

According to our LPI (LP Information) latest study, the global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer market size was valued at US\$ million in 2023. With growing demand in downstream market, the Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer is forecast to a readjusted size of US\$ million by 2030 with a CAGR of % during review period.

The research report highlights the growth potential of the global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer market. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer market.

These antibodies are used to treat metastatic (spread) breast cancer. It is effective against tumors that overexpress the HER2/neu protein.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing

demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Key Features:

The report on Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer market reflects various aspects and provide valuable insights into the industry.

Market Size and Growth: The research report provide an overview of the current size and growth of the Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer market. It may include historical data, market segmentation by Type (e.g., Pertuzumab, Trastuzumab), and regional breakdowns.

Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.

Competitive Landscape: The research report provides analysis of the competitive landscape within the Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.

Technological Developments: The research report can delve into the latest technological developments in the Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer industry. This include advancements in Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer technology, Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer new entrants, Mono-Antibody (mAb) for

HER2-Positive Advanced Breast Cancer new investment, and other innovations that are shaping the future of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer.

Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer market. It includes factors influencing customer ' purchasing decisions, preferences for Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer product.

Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer market. The report also evaluates the effectiveness of these policies in driving market growth.

Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer market.

Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.

Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer market.

Market Segmentation:

Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.

Segmentation by type

Pertuzumab

Trastuzumab

Segmentation by application

Combination Therapy

Mono Therapy

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Roche

BOC Sciences

LGM Pharma

Biotechnica Pharma Global

KinBio

Merck

Key Questions Addressed in this Report

What is the 10-year outlook for the global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer market?

What factors are driving Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer market opportunities vary by end market size?

How does Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer break out type, application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

2.1.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Annual Sales 2019-2030

2.1.2 World Current & Future Analysis for Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer by Geographic Region, 2019, 2023 & 2030

2.1.3 World Current & Future Analysis for Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer by Country/Region, 2019, 2023 & 2030

2.2 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Segment by Type

2.2.1 Pertuzumab

2.2.2 Trastuzumab

2.3 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Type

2.3.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Type (2019-2024)

2.3.2 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue and Market Share by Type (2019-2024)

2.3.3 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sale Price by Type (2019-2024)

2.4 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Segment by Application

2.4.1 Combination Therapy

2.4.2 Mono Therapy

2.5 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Application

2.5.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sale Market Share by Application (2019-2024)

2.5.2 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue and Market Share by Application (2019-2024)

2.5.3 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sale Price by Application (2019-2024)

3 GLOBAL MONO-ANTIBODY (MAB) FOR HER2-POSITIVE ADVANCED BREAST CANCER BY COMPANY

3.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Breakdown Data by Company

3.1.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Annual Sales by Company (2019-2024)

3.1.2 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Company (2019-2024)

3.2 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Annual Revenue by Company (2019-2024)

3.2.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Company (2019-2024)

3.2.2 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Company (2019-2024)

3.3 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sale Price by Company

3.4 Key Manufacturers Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Location Distribution

3.4.2 Players Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR MONO-ANTIBODY (MAB) FOR HER2-POSITIVE ADVANCED BREAST CANCER BY GEOGRAPHIC REGION

4.1 World Historic Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Geographic Region (2019-2024)

4.1.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Annual Sales by Geographic Region (2019-2024)

4.1.2 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Annual Revenue by Geographic Region (2019-2024)

4.2 World Historic Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Country/Region (2019-2024)

4.2.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Annual Sales by Country/Region (2019-2024)

4.2.2 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Annual Revenue by Country/Region (2019-2024)

4.3 Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Growth

4.4 APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Growth

4.5 Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Growth

4.6 Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Growth

5 AMERICAS

5.1 Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Country

5.1.1 Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Country (2019-2024)

5.1.2 Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Country (2019-2024)

5.2 Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Type

5.3 Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Region

6.1.1 APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Region (2019-2024)

6.1.2 APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Region (2019-2024)

6.2 APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Type

6.3 APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer by Country

7.1.1 Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Country (2019-2024)

7.1.2 Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Country (2019-2024)

7.2 Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Type

7.3 Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer by Country

8.1.1 Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Country (2019-2024)

8.1.2 Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Country (2019-2024)

8.2 Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Type

8.3 Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer

10.3 Manufacturing Process Analysis of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer

10.4 Industry Chain Structure of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Distributors

11.3 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Customer

12 WORLD FORECAST REVIEW FOR MONO-ANTIBODY (MAB) FOR HER2-POSITIVE ADVANCED BREAST CANCER BY GEOGRAPHIC REGION

12.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Forecast by Region

12.1.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Forecast by Region (2025-2030)

12.1.2 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Annual Revenue Forecast by Region (2025-2030)

12.2 Americas Forecast by Country

12.3 APAC Forecast by Region

12.4 Europe Forecast by Country

12.5 Middle East & Africa Forecast by Country

12.6 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Forecast by Type

12.7 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Forecast by Application

13 KEY PLAYERS ANALYSIS

13.1 Roche

13.1.1 Roche Company Information

13.1.2 Roche Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Portfolios and Specifications

13.1.3 Roche Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales, Revenue, Price and Gross Margin (2019-2024)

13.1.4 Roche Main Business Overview

13.1.5 Roche Latest Developments

13.2 BOC Sciences

13.2.1 BOC Sciences Company Information

13.2.2 BOC Sciences Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Portfolios and Specifications

13.2.3 BOC Sciences Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales, Revenue, Price and Gross Margin (2019-2024)

13.2.4 BOC Sciences Main Business Overview

13.2.5 BOC Sciences Latest Developments

13.3 LGM Pharma

13.3.1 LGM Pharma Company Information

13.3.2 LGM Pharma Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Portfolios and Specifications

13.3.3 LGM Pharma Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales, Revenue, Price and Gross Margin (2019-2024)

13.3.4 LGM Pharma Main Business Overview

13.3.5 LGM Pharma Latest Developments

13.4 Biotechnica Pharma Global

13.4.1 Biotechnica Pharma Global Company Information

13.4.2 Biotechnica Pharma Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Portfolios and Specifications

13.4.3 Biotechnica Pharma Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales, Revenue, Price and Gross Margin (2019-2024)

13.4.4 Biotechnica Pharma Global Main Business Overview

13.4.5 Biotechnica Pharma Global Latest Developments

13.5 KinBio

13.5.1 KinBio Company Information

13.5.2 KinBio Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Portfolios and Specifications

13.5.3 KinBio Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales, Revenue, Price and Gross Margin (2019-2024)

13.5.4 KinBio Main Business Overview

13.5.5 KinBio Latest Developments

13.6 Merck

13.6.1 Merck Company Information

13.6.2 Merck Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Portfolios and Specifications

13.6.3 Merck Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales, Revenue, Price and Gross Margin (2019-2024)

13.6.4 Merck Main Business Overview

13.6.5 Merck Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & (\$ millions)

Table 2. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & (\$ millions)

Table 3. Major Players of Pertuzumab

Table 4. Major Players of Trastuzumab

Table 5. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Type (2019-2024) & (Kilograms)

Table 6. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Type (2019-2024)

Table 7. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Type (2019-2024) & (\$ million)

Table 8. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Type (2019-2024)

Table 9. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sale Price by Type (2019-2024) & (US\$/Gram)

Table 10. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Application (2019-2024) & (Kilograms)

Table 11. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Application (2019-2024)

Table 12. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Application (2019-2024)

Table 13. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Application (2019-2024)

Table 14. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sale Price by Application (2019-2024) & (US\$/Gram)

Table 15. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Company (2019-2024) & (Kilograms)

Table 16. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Company (2019-2024)

Table 17. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Company (2019-2024) (\$ Millions)

Table 18. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Company (2019-2024)

Table 19. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer

Sale Price by Company (2019-2024) & (US\$/Gram)

Table 20. Key Manufacturers Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Producing Area Distribution and Sales Area

Table 21. Players Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Products Offered

Table 22. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)

Table 23. New Products and Potential Entrants

Table 24. Mergers & Acquisitions, Expansion

Table 25. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Geographic Region (2019-2024) & (Kilograms)

Table 26. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share Geographic Region (2019-2024)

Table 27. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Geographic Region (2019-2024) & (\$ millions)

Table 28. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Geographic Region (2019-2024)

Table 29. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Country/Region (2019-2024) & (Kilograms)

Table 30. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Country/Region (2019-2024)

Table 31. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Country/Region (2019-2024) & (\$ millions)

Table 32. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Country/Region (2019-2024)

Table 33. Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Country (2019-2024) & (Kilograms)

Table 34. Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Country (2019-2024)

Table 35. Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Country (2019-2024) & (\$ Millions)

Table 36. Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Country (2019-2024)

Table 37. Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Type (2019-2024) & (Kilograms)

Table 38. Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Application (2019-2024) & (Kilograms)

Table 39. APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Region (2019-2024) & (Kilograms)

Table 40. APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Region (2019-2024)

Table 41. APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Region (2019-2024) & (\$ Millions)

Table 42. APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Region (2019-2024)

Table 43. APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Type (2019-2024) & (Kilograms)

Table 44. APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Application (2019-2024) & (Kilograms)

Table 45. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Country (2019-2024) & (Kilograms)

Table 46. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Country (2019-2024)

Table 47. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Country (2019-2024) & (\$ Millions)

Table 48. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Country (2019-2024)

Table 49. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Type (2019-2024) & (Kilograms)

Table 50. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Application (2019-2024) & (Kilograms)

Table 51. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Country (2019-2024) & (Kilograms)

Table 52. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Country (2019-2024)

Table 53. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Country (2019-2024) & (\$ Millions)

Table 54. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Country (2019-2024)

Table 55. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Type (2019-2024) & (Kilograms)

Table 56. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Application (2019-2024) & (Kilograms)

Table 57. Key Market Drivers & Growth Opportunities of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer

Table 58. Key Market Challenges & Risks of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer

Table 59. Key Industry Trends of Mono-Antibody (mAb) for HER2-Positive Advanced

Breast Cancer

Table 60. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Raw Material

Table 61. Key Suppliers of Raw Materials

Table 62. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Distributors List

Table 63. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Customer List

Table 64. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Forecast by Region (2025-2030) & (Kilograms)

Table 65. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Forecast by Region (2025-2030) & (\$ millions)

Table 66. Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Forecast by Country (2025-2030) & (Kilograms)

Table 67. Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Forecast by Country (2025-2030) & (\$ millions)

Table 68. APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Forecast by Region (2025-2030) & (Kilograms)

Table 69. APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Forecast by Region (2025-2030) & (\$ millions)

Table 70. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Forecast by Country (2025-2030) & (Kilograms)

Table 71. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Forecast by Country (2025-2030) & (\$ millions)

Table 72. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Forecast by Country (2025-2030) & (Kilograms)

Table 73. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Forecast by Country (2025-2030) & (\$ millions)

Table 74. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Forecast by Type (2025-2030) & (Kilograms)

Table 75. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Forecast by Type (2025-2030) & (\$ Millions)

Table 76. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Forecast by Application (2025-2030) & (Kilograms)

Table 77. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Forecast by Application (2025-2030) & (\$ Millions)

Table 78. Roche Basic Information, Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Manufacturing Base, Sales Area and Its Competitors

Table 79. Roche Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer

Product Portfolios and Specifications

Table 80. Roche Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales (Kilograms), Revenue (\$ Million), Price (US\$/Gram) and Gross Margin (2019-2024)

Table 81. Roche Main Business

Table 82. Roche Latest Developments

Table 83. BOC Sciences Basic Information, Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Manufacturing Base, Sales Area and Its Competitors

Table 84. BOC Sciences Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Portfolios and Specifications

Table 85. BOC Sciences Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales (Kilograms), Revenue (\$ Million), Price (US\$/Gram) and Gross Margin (2019-2024)

Table 86. BOC Sciences Main Business

Table 87. BOC Sciences Latest Developments

Table 88. LGM Pharma Basic Information, Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Manufacturing Base, Sales Area and Its Competitors

Table 89. LGM Pharma Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Portfolios and Specifications

Table 90. LGM Pharma Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales (Kilograms), Revenue (\$ Million), Price (US\$/Gram) and Gross Margin (2019-2024)

Table 91. LGM Pharma Main Business

Table 92. LGM Pharma Latest Developments

Table 93. Biotechnica Pharma Global Basic Information, Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Manufacturing Base, Sales Area and Its Competitors

Table 94. Biotechnica Pharma Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Portfolios and Specifications

Table 95. Biotechnica Pharma Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales (Kilograms), Revenue (\$ Million), Price (US\$/Gram) and Gross Margin (2019-2024)

Table 96. Biotechnica Pharma Global Main Business

Table 97. Biotechnica Pharma Global Latest Developments

Table 98. KinBio Basic Information, Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Manufacturing Base, Sales Area and Its Competitors

Table 99. KinBio Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Portfolios and Specifications

Table 100. KinBio Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer

Sales (Kilograms), Revenue (\$ Million), Price (US\$/Gram) and Gross Margin
(2019-2024)

Table 101. KinBio Main Business

Table 102. KinBio Latest Developments

Table 103. Merck Basic Information, Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Manufacturing Base, Sales Area and Its Competitors

Table 104. Merck Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Portfolios and Specifications

Table 105. Merck Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales (Kilograms), Revenue (\$ Million), Price (US\$/Gram) and Gross Margin (2019-2024)

Table 106. Merck Main Business

Table 107. Merck Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer

Figure 2. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Growth Rate 2019-2030 (Kilograms)

Figure 7. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Growth Rate 2019-2030 (\$ Millions)

Figure 8. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Region (2019, 2023 & 2030) & (\$ Millions)

Figure 9. Product Picture of Pertuzumab

Figure 10. Product Picture of Trastuzumab

Figure 11. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Type in 2023

Figure 12. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Type (2019-2024)

Figure 13. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumed in Combination Therapy

Figure 14. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market: Combination Therapy (2019-2024) & (Kilograms)

Figure 15. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumed in Mono Therapy

Figure 16. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market: Mono Therapy (2019-2024) & (Kilograms)

Figure 17. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Application (2023)

Figure 18. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Application in 2023

Figure 19. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market by Company in 2023 (Kilograms)

Figure 20. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Company in 2023

Figure 21. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue

Market by Company in 2023 (\$ Million)

Figure 22. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Company in 2023

Figure 23. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Geographic Region (2019-2024)

Figure 24. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Geographic Region in 2023

Figure 25. Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales 2019-2024 (Kilograms)

Figure 26. Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue 2019-2024 (\$ Millions)

Figure 27. APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales 2019-2024 (Kilograms)

Figure 28. APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue 2019-2024 (\$ Millions)

Figure 29. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales 2019-2024 (Kilograms)

Figure 30. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue 2019-2024 (\$ Millions)

Figure 31. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales 2019-2024 (Kilograms)

Figure 32. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue 2019-2024 (\$ Millions)

Figure 33. Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Country in 2023

Figure 34. Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Country in 2023

Figure 35. Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Type (2019-2024)

Figure 36. Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Application (2019-2024)

Figure 37. United States Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Growth 2019-2024 (\$ Millions)

Figure 38. Canada Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Growth 2019-2024 (\$ Millions)

Figure 39. Mexico Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Growth 2019-2024 (\$ Millions)

Figure 40. Brazil Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Growth 2019-2024 (\$ Millions)

- Figure 41. APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Region in 2023
- Figure 42. APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Regions in 2023
- Figure 43. APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Type (2019-2024)
- Figure 44. APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Application (2019-2024)
- Figure 45. China Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Growth 2019-2024 (\$ Millions)
- Figure 46. Japan Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Growth 2019-2024 (\$ Millions)
- Figure 47. South Korea Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Growth 2019-2024 (\$ Millions)
- Figure 48. Southeast Asia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Growth 2019-2024 (\$ Millions)
- Figure 49. India Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Growth 2019-2024 (\$ Millions)
- Figure 50. Australia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Growth 2019-2024 (\$ Millions)
- Figure 51. China Taiwan Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Growth 2019-2024 (\$ Millions)
- Figure 52. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Country in 2023
- Figure 53. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Country in 2023
- Figure 54. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Type (2019-2024)
- Figure 55. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Application (2019-2024)
- Figure 56. Germany Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Growth 2019-2024 (\$ Millions)
- Figure 57. France Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Growth 2019-2024 (\$ Millions)
- Figure 58. UK Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Growth 2019-2024 (\$ Millions)
- Figure 59. Italy Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Growth 2019-2024 (\$ Millions)
- Figure 60. Russia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer

Revenue Growth 2019-2024 (\$ Millions)

Figure 61. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Country in 2023

Figure 62. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Country in 2023

Figure 63. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Type (2019-2024)

Figure 64. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Application (2019-2024)

Figure 65. Egypt Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Growth 2019-2024 (\$ Millions)

Figure 66. South Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Growth 2019-2024 (\$ Millions)

Figure 67. Israel Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Growth 2019-2024 (\$ Millions)

Figure 68. Turkey Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Growth 2019-2024 (\$ Millions)

Figure 69. GCC Country Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Growth 2019-2024 (\$ Millions)

Figure 70. Manufacturing Cost Structure Analysis of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer in 2023

Figure 71. Manufacturing Process Analysis of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer

Figure 72. Industry Chain Structure of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer

Figure 73. Channels of Distribution

Figure 74. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Forecast by Region (2025-2030)

Figure 75. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share Forecast by Region (2025-2030)

Figure 76. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share Forecast by Type (2025-2030)

Figure 77. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share Forecast by Type (2025-2030)

Figure 78. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share Forecast by Application (2025-2030)

Figure 79. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share Forecast by Application (2025-2030)

I would like to order

Product name: Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Growth 2024-2030

Product link: <https://marketpublishers.com/r/GC0517890A2DEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GC0517890A2DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

